Advertisement

Topics

Optibiotix Health focused on marketing and ramping up revenues

10:38 EDT 27 Oct 2017 | Proactive Investors

Proactive Investors sits down with Per Rehne, commercial director of OptiBiotix Health plc (LON:OPTI).

The human microbiome specialist's recently agreed for its cholesterol and blood pressure reducing LP-LDL strain to be sold in Spain, Chile, Peru and the Middle East in a three-year deal with Galenicum Special Ingredients.

The non-exclusive deal will see LP-LDL added to Galenicum's STOP&GO range of capsules, which are sold under the brand Cardiocare.

Original Article: Optibiotix Health focused on marketing and ramping up revenues

NEXT ARTICLE

More From BioPortfolio on "Optibiotix Health focused on marketing and ramping up revenues"

Advertisement
Quick Search
Advertisement
Advertisement